Postpartum Depression Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | SAGE Therapeutics, GH Research, Bristol-Myers Squibb

DelveInsight’s “Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Postpartum Depression, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Postpartum Depression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postpartum Depression Market Forecast

Some of the key facts of the Postpartum Depression Market Report

• The Postpartum Depression market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• There were 1,169,000 diagnosed prevalent cases of PPD among mothers in the 7MM overall in 2022, and this number is expected to rise during the projected period
• France had the most moms with PPD who had been diagnosed with the condition overall in 2022, making up almost 32% of all cases in the EU4
• Japan accounted for 10% of the total diagnosed prevalent cases of PPD in women across the 7MM nations in 2022. Throughout the projected period, these cases are anticipated to rise even more
• In October 2021, The present data package for zuranolone, according to Biogen and Sage Therapeutics, is sufficient to move forward with submissions in MDD in the second half of 2022 and postpartum depression (PPD) the following year
• Key Postpartum Depression Companies: SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb, and others
• Key Postpartum Depression Therapies: Zuranolone(SAGE-217), BRII-296, RE104, GH001, Brexanolone, aripiprazole, and others
• The Postpartum Depression epidemiology based on gender analyzed that PPD majorly affects females but a small proportion of males can also experience depression post-pregnancy
• The Postpartum Depression market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Postpartum Depression pipeline products will significantly revolutionize the Postpartum Depression market dynamics.

Postpartum Depression Overview

About 10-15% of women have postpartum depression (PPD), which is the most prevalent non-psychotic pregnancy consequence. As a result, PPD is a serious public health issue that affects both women and their families. It is generally known that there is a higher chance of major mood problems developing during the postnatal period.

Get a Free sample for the Postpartum Depression Market Report 

https://www.delveinsight.com/report-store/postpartum-depression-ppd-market

Postpartum Depression Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Postpartum Depression Epidemiology Segmentation:

The Postpartum Depression market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Postpartum Depression
• Prevalent Cases of Postpartum Depression by severity
• Gender-specific Prevalence of Postpartum Depression
• Diagnosed Cases of Episodic and Chronic Postpartum Depression

Download the report to understand which factors are driving Postpartum Depression epidemiology trends @ Postpartum Depression Epidemiology Forecast

Postpartum Depression Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postpartum Depression market or expected to get launched during the study period. The analysis covers Postpartum Depression market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Postpartum Depression Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Postpartum Depression Therapies and Key Companies

• Zuranolone(SAGE-217): SAGE Therapeutics
• BRII-296: Brii Biosciences Limited
• RE104: Reunion Neuroscience
• GH001: GH Research
• Brexanolone: Sage Therapeutics
• aripiprazole: Bristol-Myers Squibb

Discover more about therapies set to grab major Postpartum Depression market share @ Postpartum Depression Treatment Market

Postpartum Depression Market Drivers

• ZULRESSO starts working within 2–3 days of the administration, drastically improving the response rates compared to conventional therapies
• Therapies like BRII-296 and LPCN-1154 are in early stages of clinical development and their approval in future can help the PPD therapeutic market grow tremendously.

Postpartum Depression Market Barriers

• Limited therapies are available for treating and diagnosing PPD, thus providing profitable opportunities for emerging therapies
• Increasing research and development to establish the pathophysiology and recent advancement in the diagnosis gives alucrative opportunity for the PPD market

Scope of the Postpartum Depression Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Postpartum Depression Companies: SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb, and others
• Key Postpartum Depression Therapies: Zuranolone(SAGE-217), BRII-296, RE104, GH001, Brexanolone, aripiprazole, and others
• Postpartum Depression Therapeutic Assessment: Postpartum Depression current marketed and Postpartum Depression emerging therapies
• Postpartum Depression Market Dynamics: Postpartum Depression market drivers and Postpartum Depression market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Postpartum Depression Unmet Needs, KOL’s views, Analyst’s views, Postpartum Depression Market Access and Reimbursement 

To know more about Postpartum Depression companies working in the treatment market, visit @ Postpartum Depression Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Postpartum Depression Market Report Introduction

2. Executive Summary for Postpartum Depression

3. SWOT analysis of Postpartum Depression

4. Postpartum Depression Patient Share (%) Overview at a Glance

5. Postpartum Depression Market Overview at a Glance

6. Postpartum Depression Disease Background and Overview

7. Postpartum Depression Epidemiology and Patient Population

8. Country-Specific Patient Population of Postpartum Depression 

9. Postpartum Depression Current Treatment and Medical Practices

10. Postpartum Depression Unmet Needs

11. Postpartum Depression Emerging Therapies

12. Postpartum Depression Market Outlook

13. Country-Wise Postpartum Depression Market Analysis (2019–2032)

14. Postpartum Depression Market Access and Reimbursement of Therapies

15. Postpartum Depression Market Drivers

16. Postpartum Depression Market Barriers

17.  Postpartum Depression Appendix

18. Postpartum Depression Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services